Lundbeck and Teva launch Azilect in France
pharmafile | January 20, 2010 | News story | Sales and Marketing | Azilect, France, Lundbeck, Teva
Lundbeck and Teva France have launched Azilect in France following the successful conclusion of pricing and reimbursement discussions with the French health authorities.
Azilect (rasagiline) will be co-promoted by Teva and Lundbeck in the European pharma market and outside Europe by Lundbeck.
Europe accounts for nearly half of the global market for Parkinson’s treatments and France is the fifth largest European market, with estimated annual sales of more than 100 million euros.
Stig Lokke Pederson, executive vice president of commercial operations at Lundbeck, said: “The reimbursement of Azilect is of great importance to the many patients in France suffering from Parkinson’s disease. Azilect is the first and only product that has demonstrated effect on slowing clinical progression of Parkinson’s disease and we are looking forward to providing it to the French market.
Azilect is indicated for the treatment of Parkinson’s disease, both as an initial monotherapy in early disease and as adjunct to levodopa later in the disease. It is currently available in 38 countries including: the US, Canada, Israel and Mexico.
Parkinson’s Disease is a brain disorder that causes muscle tremor, stiffness, and weakness. Early symptoms of Parkinson’s disease include muscular stiffness, a tendency to tire more easily than usual, and trembling that usually begins with a slight tremor in one hand, arm, or leg.
In the later stages of Parkinson’s disease, the affected person loses the ability to control their movements, and the intellect begins to be affected by the disease. About one-third of Parkinson’s disease sufferers eventually show signs of dementia. The disease runs an average ten-year course and ultimately results in death usually by an infection or aspiration pneumonia.
One person in 200 will get Parkinson’s Disease during their lifetime with the risk increasing with age (one in every 100 persons over 60 has Parkinson’s). The disease is more common in men than in women.
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug
Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …
